C12N 2740/17011
Spumavirus
Official title: Spumavirus, e.g. chimpanzee foamy virus
C12N2740/17011 (Spumavirus) appears on 40 US grants and 40 published applications in this corpus.
Search patents in C12N- Granted patents
- 40
- Published applications
- 40
- Assignees
- 27
- Inventors
- 77
- Latest grant
- 21 Jan 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 8 | 0 |
| 2001 | 4 | 1 |
| 2002 | 3 | 0 |
| 2003 | 2 | 2 |
| 2004 | 4 | 3 |
| 2005 | 1 | 2 |
| 2006 | 1 | 0 |
| 2007 | 2 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 3 |
| 2010 | 1 | 3 |
| 2011 | 1 | 2 |
| 2012 | 3 | 4 |
| 2013 | 1 | 0 |
| 2014 | 0 | 2 |
| 2015 | 2 | 2 |
| 2016 | 0 | 3 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/17022New viral proteins or individual genes, new structural or functional aspects ofIndexing code37
- C12N 2740/17041Use of virus, viral particle or viral elements as a vectorIndexing code8
- C12N 2740/17021Viruses as suchIndexing code6
- C12N 2740/17032Use of virus as therapeutic agent, other than vaccineIndexing code2
- C12N 2740/17051Methods of production or purification of viral materialIndexing code2
- C12N 2740/17023Virus like particles [vlp]Indexing code0
- C12N 2740/17031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2740/17033Use of viral protein as therapeutic agent other than vaccineIndexing code0
Recent patents
- Foamy viruses and methods of use21 Jan 2025US 12,201,659 B2Mayo Foundation for Medical Education and Research
- Beta-2 microglobulin-deficient cells14 Nov 2023US 11,813,318 B2University of Washington
- RNA based method to obtain stably integrated retroviral vectors13 Aug 2019US 10,378,026 B2Cellectis
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use15 Sep 2015US 9,133,483 B2The Trustees of the University of Pennsylvania
- Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures21 Apr 2015US 9,012,618 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Foamy viruses and methods of use3 Apr 2025US 2025/0108079 A1Mayo Foundation for Medical Education and Research
- Targeted retroviral integration for treatment of genetic disorders26 Dec 2024US 2024/0425828 A1Ohio State Innovation Foundation
- Beta-2 microglobulin-deficient cells27 Jun 2024US 2024/0207378 A1University of Washington through its Center for Commercialization
- Foamy viral vector compositions and methods for the manufacture of same24 Feb 2022US 2022/0056477 A1Children's Hospital Medical Center
Most cited
By later US patents
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use50US 8,105,574 B2The Trustees of the University of Pennsylvania · 2012
- Simian immunodeficiency virus peptides with antifusogenic and antiviral activities47US 6,017,536 ATrimeris, Inc. · 2000
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use46US 8,603,459 B2The Trustees of the University of Pennsylvania · 2013
- Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission37US 6,060,065 ADuke University · 2000